The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
In a step that could lead to a new diabetes treatment, several Boston-area hospitals have teamed up with the Harvard Stem Cell Institute and biotech Semma Therapeutics toย make personalized cell-based therapiesย and organize clinical trials.
It is one of several initiatives around the country aimed at manufacturing cell-derived treatments, as the hope for such therapiesย creates a demand for the productionย of the cells.
โItโs going to be very expensive,โ said Dr. Richard Lee, a Brigham cardiologist and researcher at the stem cell institute. โThe big challenge is, can the strategy of using an individualโs stem cells come down to a price thatโs really feasible?โ
Share this article
Organizers of the Boston program still need to secure more funding if it is going to be successful. The stem cell institute has committed to funding the program for the first year, but Lee and other Harvard officials would not say how much the institute is contributing, or how much they think the program will cost to sustain.
Read full, original post: Stem cell factory opens door for trials of personalized diabetes treatment
